If you have been reading about GLP-1 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Nitrosoprodenafil is a synthetic designer drug found in "herbal" aphrodisiac products, which is a novel nitrosated analogue of sildenafil (Viagra). It has an innovative structure which acts as a prodrug, breaking down in the body to release both the PDE5 inhibitor aildenafil as well as free nitric oxide, which have powerfully synergistic effects. This dual mechanism of action has never been exploited by conventional pharmaceutical companies because of the risks involved; usually combining PDE5 inhibitors with nitric oxide releasers like amyl nitrite is contraindicated as it can cause a precipitous drop in blood pressure that can potentially result in death. Nitrosamines are also generally avoided in drug development as they can often be hepatotoxic and carcinogenic, so while the combined mechanisms of action are likely to be effective, this drug also has severe risks of toxicity. Shortly after Venhuis et al. published the suggested structure for nitrosoprodenafil, it was contested by Demizu et al. who suggested the structure was an azathioprine/aildenafil hybrid. This newly suggested structure was dubbed 'mutaprodenafil' because of the structural similarity with the mutagenic immunosuppressive drug azathioprine. The final confirmation of the azathioprine/aildenafil hybrid was provided by Sakamoto et al. who prepared crystals for X-ray analysis. Although Sakamoto et al. support the name 'mutaprodenafil', they prefer to use 'nitrosoprodenafil' instead.
In addition, several viruses, including the AIDS virus HIV, have binding sites for NF-κB that controls the expression of viral genes, which in turn contribute to viral replication or viral pathogenicity. In the case of HIV-1, activation of NF-κB may, at least in part, be involved in activation of the virus from a latent, inactive state. YopP is a factor secreted by Yersinia pestis, the causative agent of plague, that prevents the ubiquitination of IκB. This causes this pathogen to effectively inhibit the NF-κB pathway and thus block the immune response of a human infected with Yersinia.
The vast majority of genetically modified animals are at the research stage with the number close to entering the market remaining small. As of 2018 only three genetically modified animals have been approved, all in the USA. A goat and a chicken have been engineered to produce medicines and a salmon to increase its growth. Despite the differences and difficulties in modifying them, the end aims are much the same as for plants. GM animals are created for research purposes, production of industrial or therapeutic products, agricultural uses, or improving their health. There is also a market for creating genetically modified pets.
Psilocybin is dephosphorylated into its active form psilocin in the body and hence is a prodrug. Psilocybin is metabolized in the intestines, liver, kidneys, blood, and other tissues and bodily fluids. There is significant first-pass metabolism of psilocybin and psilocin with oral administration. No psilocybin has been detected in the blood in humans after oral administration, suggesting virtually complete dephosphorylation into psilocin with the first pass. It is also said to be converted 90% to 97% into psilocin. The competitive phosphatase inhibitor β-glycerolphosphate, which inhibits psilocybin dephosphorylation, greatly attenuates the behavioral effects of psilocybin in rodents. Psilocybin undergoes dephosphorylation into psilocin via the acidic environment of the stomach or the actions of alkaline phosphatase (ALP) and non-specific esterases in tissues and fluids. Psilocin is demethylated and oxidatively deaminated by monoamine oxidase (MAO), specifically monoamine oxidase A (MAO-A), into 4-hydroxyindole-3-acetaldehyde (4-HIAL or 4-HIA). 4-HIAL is then further oxidated into 4-hydroxyindole-3-acetic acid (4-HIAA) by aldehyde dehydrogenase (ALDH) or into 4-hydroxytryptophol (4-HTOL or 4-HTP) by alcohol dehydrogenase (ALD). Deamination of psilocin by MAO-A appears to be responsible for about 4% or 33% of its metabolism in different studies. In contrast to psilocin, its metabolites 4-HIAA and 4-HTP showed no affinity for or activation of multiple serotonin receptors and are considered inactive.
Plasmin is an important enzyme (EC 3.4.21.7) present in blood that degrades many blood plasma proteins, including fibrin clots. The degradation of fibrin is termed fibrinolysis. In humans, the plasmin protein (in the zymogen form of plasminogen) is encoded by the PLG gene.
Sources: en.wikipedia.org
==== Volumetric analysis ==== Titration involves the gradual addition of a measurable reactant to an exact volume of a solution being analyzed until some equivalence point is reached. Titration is a family of techniques used to determine the concentration of an analyte. Titrating accurately to either the half-equivalence point or the endpoint of a titration allows the chemist to determine the amount of moles used, which can then be used to determine a concentration or composition of the titrant. Most familiar to those who have taken chemistry during secondary education is the acid-base titration involving a color-changing pH indicator, such as phenolphthalein. There are many other types of titrations, including potentiometric titrations and precipitation titrations. Chemists might also create titration curves by systematically testing the pH after every added drop in order to understand different properties of the titrant.
Many items denoting 'rank and prestige' were deposited in the water surrounding Flag Fen, including swords, spearheads, 'gold earrings, tiny pins and brooches'. Archaeologist Francis Pryor, who discovered the site in 1982, suggests that 'settlers often vied for social status by showing they could afford to discard valuable possessions'. There is also evidence of intentional destruction before placement, e.g. daggers broken in half placed on top of each other. Other finds included small, polished, white stones of a type not known in the area, indicating that they had been intentionally collected and transported to and placed at the site. Other artefacts found were animal bones, including horse mandibles. Horses were very valuable to the prehistoric people, since they provided a means of transport and could supplement or replace man-power. For example, they could be used to carry or pull timbers on sledges over long distances. Significance is also drawn from the discovery of the ritual deposits within thirty metres of the timber post line, and only on its southern boundary. The amount, type, and placement of deposits, which continued for more than 1,200 years, support the theory that 'at least one facet of the site' was a role as a 'religious monument'. On Northey Island many round barrows contemporary with Flag Fen were found. These seemed to be constructed over the dwellings of 'chiefs'. Mike Parker Pearson refers to this as the "Land of the Dead". There is also evidence of farming, including sheep remains, contemporary with the site.
Newsom's first political experience came when he volunteered for Willie Brown's successful campaign for mayor in 1995. Newsom hosted a private fundraiser at his PlumpJack Café. Brown appointed Newsom to a vacant seat on the Parking and Traffic Commission in 1996, and he was later elected president of the commission. Brown appointed him to the San Francisco Board of Supervisors seat vacated by Kevin Shelley in 1997. At the time, he was the youngest member of San Francisco's board of supervisors. Newsom was sworn in by his father and pledged to bring his business experience to the board. Brown called Newsom "part of the future generation of leaders of this great city". Newsom described himself as a "social liberal and a fiscal watchdog". He was elected to a full four-year term to the board in 1998. San Francisco voters chose to abandon at-large elections to the board for the previous district system in 1999. Newsom was reelected in 2000 and 2002 to represent the second district, which includes Pacific Heights, the Marina, Cow Hollow, Sea Cliff, and Laurel Heights, which had San Francisco's highest income level and highest Republican registration. Newsom paid $500 to the San Francisco Republican Party to appear on the party's endorsement slate in 2000 while running for Supervisor. He was reelected. As a San Francisco Supervisor, Newsom gained public attention for his role in advocating reform of the city's municipal railway (Muni). He was one of two supervisors endorsed by Rescue Muni, a transit riders group, in his 1998 reelection.
He also learns that Wellington Wells is slowly falling apart; the city's infrastructure is failing, an unspecified disease outbreak has occurred, and Joy is becoming less effective, with scientist Anton Verloc (Michael Shaeffer) researching a new version of Joy to permanently lobotomize the populace and keep them in a never-ending state of euphoria. Eventually, Arthur reaches a railway bridge leading out of Wellington Wells, and recalls that he swapped his identity card (which stated his age as 12) with Percy's (who had just turned 13) before the children of Wellington Wells boarded the fateful train to Germany, effectively sacrificing his brother to save himself. Sally's Story: The creator of a new brand of Joy, Sally Boyle (Charlotte Hope), works as an experimental chemist in her laboratory after being kicked out of Haworth Labs by its director, Anton Verloc. The local police constabulary threaten Sally into supplying them with her Joy, which forces her to scrounge the city for new ingredients to create a fresh batch. Sally is secretly a mother to the first baby born in Wellington Wells in a long time: Gwen, who Verloc fathered. When Gwen becomes sick with measles, Sally asks Arthur, her childhood friend, to find a bottle of cod liver oil. Arthur, not knowing it is for Gwen, agrees in return for a Letter of Transit from General Robert Byng (Stephen Boxer), Sally's most prominent patron and on-and-off lover. Sally eventually remembers how her mother poisoned her family when she and her siblings were to be taken to Germany, leaving Sally as the sole survivor.
While reef-forming corals are almost entirely restricted to warm and shallow marine waters, other cnidarians can be found at great depths, in polar regions, and in freshwater. Cnidarians are a very ancient phylum, with fossils having been found in rocks formed about 580 million years ago during the Ediacaran period, preceding the Cambrian Explosion. Other fossils show that corals may have been present shortly before 490 million years ago and diversified a few million years later. Molecular clock analysis of mitochondrial genes suggests an even older age for the crown group of cnidarians, estimated around 741 million years ago, almost 200 million years before the Cambrian period, as well as before any fossils. Recent phylogenetic analyses support monophyly of cnidarians, as well as the position of cnidarians as the sister group of bilaterians.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.